The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including PIER (Physicians' Information and Education Resource) and MKSAP (Medical Knowledge and SelfAssessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of science writers and physician writers. Editorial consultants from PIER and MKSAP provide expert review of the content. Readers who are interested in these primary resources for more detail can consult http://pier.acponline.org, http://www.acponline.org/products_services/ mksap/15/?pr31, and other resources referenced in each issue of In the Clinic. CME Objective: To review current evidence for the prevention, presentation and diagnosis, treatment, and practice improvement of acute gastrointestinal bleeding.
A cute gastrointestinal (GI) bleeding is common in both the outpatient setting and the emergency department. Annual U.S. incidence rates over the past decade are approximately 90-108 per 100 000 persons (1), leading to approximately 300 000 hospitalizations annually. Most cases are due to nonvariceal sources of bleeding (e.g., peptic ulcers) and continue to be associated with significant mortality (3-14%) and health economic burden (1-3). The incidence of nonvariceal bleeding may be decreasing in the West largely because of decreased incidence of Helicobacter pylori infection and increased awareness and implementation of ulcer-prevention strategies in users of nonsteroidal antiinflammatory drugs (NSAIDs) (1). However, identifying patients with acute GI bleeding who are in danger of serious adverse events and establishing evidencebased treatment plans are essential in both primary and specialty care.
with lower GI bleeding include inflammatory bowel disease, infectious colitis, neoplasia, angioectasias, and benign anorectal disease (14) .
Approximately 10-20% of patients with GI bleeding have "obscure" bleeding, defined as an unknown cause despite evaluation with esophagogastroduodenoscopy (EGD), colonoscopy, and radiographic small bowel imaging. Approximately half of these patients have recurrent or persistent bleeding and are further subclassified as obscure-overt (passage of visible blood with melena or hematochezia) or obscure-occult (iron-deficiency anemia and/or positive for fecal occult blood) (15). Many such patients have bleeding sources in the small intestine, now sometimes referred to as "mid-GI bleeding" (between the ligament of Treitz and the ileocecal valve). Angioectasia is the most common cause of small-bowel bleeding in the West, accounting for 70-80% of cases (16).
Can acute GI bleeding be prevented?
Prevention of acute GI bleeding depends on the risk factors and causes. For example, reducing use of NSAIDs and administering antacid treatment with H 2 -inhibitors or proton-pump inhibitors (PPIs) prevents peptic ulcer bleeding. Prophylactic acid suppression should be considered in selected hospitalized patients who are at increased risk for gastroduodenal ulceration and bleeding, including
Who is at risk for acute GI bleeding?
Risk factors for acute GI bleeding vary according to the site and cause. Upper GI bleeding most often results from peptic ulcer disease (approximately one quarter of all cases), the primary risk factors for which include NSAIDs and H. pylori infection and, less commonly, increased gastric acid production (e.g., the Zollinger-Ellison syndrome). Smoking (4-6), severe physiologic stress (7), and various host factors (e.g., genetic polymorphisms affecting cyclooxygenase and prostaglandin production) (8, 9) may increase risk for peptic ulcers even in persons without concomitant H. pylori infection or NSAID exposure. Although spicy foods may cause GI symptoms, there are no convincing data that they increase the risk for peptic ulcers. Other risk factors for acute upper GI bleeding include varices, esophagitis, vascular abnormalities (e.g., angioectasias, arteriovenous malformations, Dieulafoy lesions), Mallory-Weiss tear from protracted vomiting, and benign and malignant neoplasms (10-13).
Lower GI bleeding, historically defined as bleeding from a source distal to the ligament of Treitz, also results from several causes with distinct risk factors. Diverticulosis is the most common cause of hematochezia, accounting for up to half of all cases, particularly in patients older than 65 years. Other risk factors associated Prevention... Risk factors for, and therefore prevention of, acute GI bleeding depends on the site and cause of bleeding. In general, minimizing use and appropriate prescribing of NSAIDs, antiplatelet agents, and anticoagulants, as well as judicious primary and secondary prophylactic acid suppression in selected patients, are effective measures for ulcer-related upper GI bleeding. Nonselective beta-blockers and endoscopic therapy for esophageal and gastric varices are effective for primary and secondary prevention of variceal bleeding. Few measures are helpful in preventing lower GI bleeding, except for reducing exposure to NSAIDS, anticoagulants, and antiplatelets. approximately 50-70% and 25-70% of cases, respectively (16). Some centers offer advanced deep enteroscopic procedures, which are low-risk and enable visualization and therapeutics deep within the small intestine, essentially eliminating the need for high-risk intraoperative enteroscopy for patients with suspected small bowel pathology.
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Presentation and Diagnosis
VCE. Another option is angiography, which allows for therapeutic intervention (embolization) if a lesion is localized; however, it requires active bleeding to be diagnostic. Computed tomography angiography or computed tomography/magnetic resonance enterography are alternative diagnostic options that identify sources of obscure bleeding in cardiovascular function, with the goal of normal, stable vital signs.
Observational studies and small controlled trials have suggested that blood transfusion to a target helmoglobin level of 9-10 mg/dL might actually be detrimental for some patients with hypovolemic anemia, including those with GI bleeding. What interventions should be started immediately in patients with acute GI bleeding? Regardless of the source, initial management of a patient with acute GI bleeding involves rapid diagnostic assessment and aggressive resuscitation with isotonic fluids via 2 large-bore (18-gauge or larger) peripheral IV catheters. Early intensive resuscitation has been associated with decreased mortality from GI bleeding (48). The goal of resuscitation is to maintain tissue perfusion until bleeding resolves spontaneously or is controlled by more definitive therapy. Smaller catheters (e.g., 20-or 22-gauge) do not allow rapid fluid administration. Longer central venous catheters increase resistance to fluid flow, thereby slowing the rate at which fluids may be given. Patients with emesis who are unable to protect the airway from aspiration should be intubated. Isotonic IV fluids, such as normal saline or lactated Ringer solution, should be given immediately, with the goal of replenishing intravascular volume as quickly as blood has been lost and as rapidly as is tolerated by the patient's underlying Presentation and Diagnosis... GI bleeding can present with myriad signs and symptoms, ranging from asymptomatic to overt hematemesis or hematochezia, and can be due to a number of causes virtually anywhere along the GI tract. Initial evaluation, including history and physical examination and routine laboratory tests, can help to narrow the differential diagnosis. monitored closely for adverse effects of volume replacement, including pulmonary edema. Targeting a hemoglobin level between 7-8 g/dL might prevent excessive restitution of blood volume and subsequent increases in portal pressure (62) .
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There are no definitive guidelines for management of coagulopathy and thrombocytopenia in patients with acute variceal hemorrhage. Reversal of coagulopathy requires administration of fresh frozen plasma, although the volume necessary may be prohibitive. Recombinant factor VIIa as an alternative means of normalizing the prothrombin time has been proposed, but randomized, controlled trials have not shown a consistent advantage (62) . Because prothrombin time-INR is not a reliable indicator of the coagulation status in patients with cirrhosis, recommendations regarding management of coagulopathy/thrombocytopenia cannot be made on the basis of available data (63).
Antibiotic prophylaxis reduces infectious complications and decreases rebleeding with acute variceal bleeding. A short-term quinolone course (e.g., up to 7 days of norfloxacin or ciprofloxacin) is recommended. Data from a few studies suggest that ceftriaxione may prevent bacterial infections better than norfloxacin, and IV ceftriaxone (1 g/day) may be preferable in patients with advanced cirrhosis and/or in regions with high prevalence of quinolone-resistant organisms (62, 64) .
Variceal bleeding can often be controlled by both medical and endoscopic means. Medical therapy primarily involves infusion of octreotide, a somatostatin analogue that causes splanchnic vasoconstriction and reduced portal pressure. Numerous trials of octreotide have yielded equivocal results, but it is recommended in combination with endoscopic therapies to control variceal bleeding and reduce risk for recurrence (18) 
. Octreotide should patients with ulcer bleeding, PPIs reduce rebleeding and need for surgery or repeated endoscopic procedures and improve mortality in the highest-risk patients (59).
The optimal dose and route of acute PPI administration remain unclear, but patients with high-risk lesions having endoscopic therapy should receive in-hospital therapy (IV, highdose therapy remains the regimen with the best evidence [22]) for 3 days, mirroring the period during which risk for rebleeding is greatest (60, 61) . In the absence of comparative data, a once-daily oral PPI is recommended after completion of 72 hours of IV therapy (22, 30, 39). H-receptor blockers are not as effective and should not replace PPIs for acute management of bleeding ulcers.
How should acute esophageal variceal bleeding be treated?
Acute bleeding from esophageal varices is frequently life-threatening because it can be severe, difficult to control, and rarely resolves spontaneously. It usually occurs in patients with end-stage liver disease. Esophageal varices are caused by significant portal hypertension; therefore, bleeding occurs under high pressure and is often brisk. In addition, patients have synthetic liver dysfunction and coagulopathy. Under these circumstances, acute management requires rapid and aggressive interventions, including fluid resuscitation, bleeding control, and efforts aimed at reducing portal pressures.
Intravascular volume replacement should occur as with any patient with acute GI hemorrhage. Resuscitation of patients with end-stage liver disease is often difficult due to hypoalbuminemia and extravasation of fluid from the intravascular space. Some experts advocate preferential use of blood products and albumin for intravascular volume resuscitation, because crystalloid fluids deliver a sodium load to patients who are typically already total-body sodium overloaded and tend to eventually exacerbate ascites. 
How should patients with acute lower GI bleeding from colonic diverticulosis be treated?
Initial management of colonic diverticular hemorrhage is the same as that for other causes of GI bleeding, including fluid resuscitation, blood transfusion, and diagnostic testing. Colonoscopy should be done to try to localize the bleeding, although with brisk hemorrhage, localization can be difficult due to poor visualization. The timing of the colonoscopy remains controversial; however, it is usually done within 12-24 hours of presentation with a rapid colonic preparation that seems to be safe in this setting (66) . The most important contribution of colonoscopy is usually exclusion of other causes. In rare cases, it can also be therapeutic if a visible vessel or adherent clot is noted. More typically, however, bleeding occurs from multiple sites and may be intermittent, so the opportunity for intervention is limited. Other studies that may localize the bleeding include nuclear imaging and angiography (19).
Bleeding resolves spontaneously in approximately 75% of patients with be given as a bolus dose of 50 µg followed by continuous IV infusion of 50 µg/hour for a total of 3 to 5 days, although many experts currently prefer a 5-day regimen (63).
Endoscopy should be done within 12 hours in patients with known or suspected varices who present with upper GI bleeding. There are 2 primary endoscopic interventions: sclerotherapy and band ligation. Sclerotherapy involves injection of a sclerosing agent (e.g., sodium morrhuate or ethanolamine) into varices. Band ligation involves wrapping elastic bands over the varices in the distal esophagus. Clinical trials have shown that compared with sclerotherapy, banding has more prolonged benefit; lower rates of rebleeding, mortality, and complications (such as esophageal stricture formation, perforation, and mediastinitis); and reduced need for endoscopic treatments (65) . Thus, band ligation has become the acute treatment of choice in most institutions.
For patients with variceal bleeding refractory to medical and endoscopic therapy, balloon tamponade (e.g., with a Sengstaken-Blakemore tube) may be used as a temporizing measure. The balloons should be inflated for no more than 12 hours. More definitive treatments include transjugular intrahepatic portosystemic shunt (TIPS) placement with a PTFE stent and surgical interventions. In patients at high risk for treatment failure (e.g., Child-Pugh class C score < 14 or class B with active bleeding), TIPS should be placed within 72 hours (63). Salvage (rescue) TIPS placement is associated with a high mortality rate. These therapies are effective and often render surgical interventions unnecessary. Surgical options include portosystemic shunting, esophageal transaction, and liver transplantation. Mortality approaches 80% for patients with continued bleeding from esophageal varices.
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How should therapy for acute GI bleeding be monitored? Continued monitoring is required to assess whether bleeding has stopped. Tachycardia may be an early warning of recurrent bleeding, followed soon by hypotension. Hemoglobin levels should be checked on a serial basis at least every several hours initially to assess for stability after blood transfusions; levels that do not increase by approximately 1 g/unit of transfused packed red blood cells may indicate ongoing blood loss. Additional blood transfusions and diagnostic testing (e.g., repeated endoscopy) should be considered if the patient has evidence of ongoing blood loss. Similarly, platelet count and coagulation should be measured serially to assess the need for repeated transfusions. Patients requiring multiple transfusions of red blood cells should be monitored for hypocalcemia.
When should a surgeon be consulted for the management of a patient with acute GI bleeding? Advances in medical and endoscopic therapies have resulted in fewer patients requiring surgery for acute GI bleeding. However, surgical consultation should be considered early in the evaluation and management of patients with severe bleeding. Surgery is indicated when life-threatening bleeding continues, hemodynamic compromise continues despite initial aggressive resuscitation, or bleeding cannot be stopped by endoscopic or angiographic means. The choice of surgery depends on bleeding location and comorbid conditions. Localization of the bleeding site is critical for surgical planning.
What follow-up outpatient evaluations are required in patients who have experienced acute GI bleeding? Specific guidelines for management of patients after discharge other than those addressing secondary prophylaxis are lacking. In general, decisions regarding timing of postdischarge outpatient visits and repeated blood diverticular hemorrhage; recurrent bleeding occurs in 25-35% of patients. If bleeding does not resolve spontaneously or with angiographic intervention, surgical resection is the remaining therapeutic option. Approximately 20% of patients hospitalized for diverticular bleeding require surgery. Segmental/ subtotal colectomy may be required if bleeding can be localized and endscopic therapy is not feasible. It may also be necessary if lower GI bleeding remains nonlocalizable, despite the risk for ongoing bleeding (due to failure to resect the actual bleeding site) and may be associated with significant morbidity and mortality (67) .
What is the role of angiography?
Angiographic interventions include local administration of vasopressin and embolization of the source. Vasopressin is a potent vasoconstrictive agent, and local instillation can control bleeding in up to 80% of patients; however, rebleeding occurs on cessation of the infusion in up to 50% of patients. Therefore, vasopressin may be most useful as a temporizing measure. Although there are no absolute contraindications, vasopressin should be used with caution in patients with coronary artery disease or peripheral vascular disease because of the risk for vasoconstriction at sites other than the target lesion. Vasopressin can also cause cardiac arrhythmia and hyponatremia.
Embolization is a common intervention for control of active hemorrhaging. It involves injection of sealant materials, such as gel foam or polyvinyl alcohol, or mechanical devices, such as coils and temporary balloons. Embolization is effective in up to 80% of cases. The primary contraindication is poor collateral blood supply. The major complications are intestinal ischemia and mechanical complications of the arterial cannulation (such as local hematoma, arterial dissection, or pseudoaneurysm).
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In Patients with cirrhosis who survive variceal hemorrhage but do not have further therapy are at significant risk for rebleeding (60%) and death (approximately 33%) within 1-2 years of the initial bleeding episode. These outcomes are improved using combined endoscopic variceal band ligation and beta-blockers (which are often given once there has been no evidence of hemorrhage for at least 24 hours, barring any contraindications). Patients who have shunt surgery or TIPS do not require further preventive measures.The American Association for the Study of Liver Disease suggests repeating endoscopy at 7-to 14-day intervals until eradication of esophageal varices has been achieved (usually requires 2-4 sessions); and once varices are eradicated, repeating endoscopy every 3-6 months initially to evaluate for recurrence and need for repeated band ligation (18). Eventually, the interval can be increased to 6-12 months.
For patients that recover from gastric ulcer bleeding, surveillance endoscopy 6 to 12 weeks after the last bleeding episode to exclude a nonhealing ulcer (which raises concern for cancer) is common in clinical practice. However, the literature recommended (70). Similarly, patients with a bleeding ulcer while receiving low-dose aspirin therapy for secondary prevention of established cardiovascular disease should resume therapy as soon as possible after cessation of bleeding (within 1 week, ideally as early as 3-5 days). Data are less robust for management of aspirin therapy after acute bleeding when aspirin is being used for primary prevention of cardiovascular events, and the risk and benefits must be weighed on an individual basis.
Patients with bleeding ulcers associated with H. pylori infection should be encouraged to complete a full course of H. pylori therapy and to have testing, such as a urea breath test or H. pylori stool antigen assay, to confirm successful eradication of the bacteria. For patients suspected of having NSAID-related ulcer bleeding, discontinuation is preferable but sometimes not feasible. If a patient must resume NSAIDs, a cyclooxygenase-2-selective NSAID at the lowest effective dose plus a daily PPI is Treatment... Treatment of GI bleeding is highly dependent on the cause and severity.
Initial evaluation and management in all cases should include history and physical examination, with simultaneous stabilization interventions, such as placement of IV access and IV fluid resuscitation. Emergent endoscopy (e.g., within 6 hours) is rarely indicated, but urgent endoscopy (e.g., within 12 h) in selected circumstances can be considered, and is mandatory if variceal bleeding is suspected. Administering a PPI is warranted in patients with suspected peptic ulcer disease but should not delay endoscopy. Transfusion practices should target a hemoglobin threshold of 7-8 g/dL. Outpatient follow-up should be individualized based on the cause of bleeding and the estimated risk for rebleeding.
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colonoscopy have been unrevealing, the American Society of Gastroenterology recommends early evaluation of the small bowel by VCE or angiography, with CT angiography, CT enteroscopy, and deep enteroscopy as secondary considerations, depending on availability and expertise at the institution.
What measures do stakeholders use to evaluate the quality of care for patients with acute GI bleeding? The Agency for Healthcare Research and Quality has identified mortality rate as the primary quality indicator for care of patients with GI bleeding. An expert panel independently developed a list of 26 quality indicators for non-variceal upper GI bleeding, categorized as preendoscopic, endoscopic, and postendoscopic factors (70).
What do professional organizations recommend with regard to the prevention, diagnosis and treatment of acute GI bleeding? The International Consensus Upper Gastrointestinal Bleeding Conference Group recommends early risk stratification and early diagnostic endoscopy in most patients with upper GI bleeding.
The American Society of Gastroenterology recommends early colonoscopy for diagnosis of acute lower GI bleeding, with angiography and tagged red blood cell scanning in patients with active bleeding and nondiagnostic colonoscopies. If surgical intervention is contemplated, preoperative localization of bleeding is desirable.
In patients with obscure acute GI bleeding in whom EGD and
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Patient Information THINGS YOU SHOULD KNOW ABOUT GASTROINTESTINAL BLEEDING
What is gastrointestinal (GI) bleeding?
• Bleeding in the digestive tract.
• The upper digestive tract includes the esophagus, stomach, and upper portion of the small intestine.
• The lower digestive tract includes lower portion of the small intestine, large intestine (also called the colon), and anus.
• Most causes of bleeding are curable or controllable, but some may be life-threatening if left untreated.
What causes bleeding in the digestive tract?
Causes of bleeding in the upper digestive tract include:
• Peptic ulcers from Helicobacter pylori infections or long-term use of nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen.
• Varices (enlarged veins) in the lower esophagus that rupture and bleed.
• Tears in the lining of the esophagus or inflammation in the lining of the stomach (gastritis) or esophagus (esophagitis).
• Cancerous or noncancerous (benign) growths.
Causes of bleeding in the lower digestive tract include:
• Diverticular disease (diverticula are irregular pouches that develop in the colon wall).
• Colitis (inflammation of the colon) or angiodysplasia (abnormalities in blood vessels of the intestine).
• Hemorrhoids (ruptured veins in the anus or rectum) or fissures (anal cuts or tears).
What are the signs and symptoms?
• Vomiting bright-red blood or vomit that looks like coffee grounds indicates bleeding in upper digestive tract.
• Black or tarry stool or stool that contains dark or bright red blood indicates bleeding in upper or lower digestive tract.
• Chronic bleeding (light bleeding that continues for a long time or starts and stops) may lead to fatigue, lethargy, and shortness of breath over time.
• Acute bleeding (heavy bleeding) may lead to dizziness or faintness, shortness of breath, abdominal pain, and shock. 
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